First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was $0, compared with $0 a year earlier.
Context
- Retained earnings amounted to 0.0% of total assets at the end of Q1 FY2026.
- Retained earnings increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Retained Earnings vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 retained earnings of $0 is the highest of the 10 companies compared; the peer median is -$532.62M.
- Retained earnings amounts to 0.0% of total assets for TRAX, versus a peer median of 250.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Jun 2026 | -$150.35M | — | — | 117.1% | |
| Jun 2026 | -$152.26M | -9.2% | — | 63.9% | |
CLYMClimb Bio, Inc. | Mar 2026 | -$303.45M | -21.1% | — | 199.2% |
| Mar 2026 | -$440.23M | -21.6% | — | 300.2% | |
| Mar 2026 | -$532.62M | -93.3% | — | 133.0% | |
| Mar 2026 | -$641.16M | -19.4% | — | 337.9% | |
| Mar 2026 | -$825.44M | -3.4% | — | 250.4% | |
| Mar 2026 | -$987.61M | -7.6% | — | 497.0% | |
| Sep 2026 | -$2B | -34.2% | — | 262.2% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | -$532.62M | -20.2% | — | 250.4% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.